Weekly Digest – October 2025 Weekly Digest – October 2025 23 October 2025: Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma The US FDA has approved Blenrep (Belantamab mafodotin) in combination with bortezomib and dexamethasone […]
Weekly Digest – October 2025 Weekly Digest – October 2025 17 October 2025: Core product Trastuzumab botidotin approved for marketing by the NMPA for 2L+ HER2+ breast cancer Sichuan Kelun-Biotech’s core product trastuzumab botidotin (A166) received marketing approval from China’s […]
Weekly Digest – October 2025 Weekly Digest – October 2025 20 October 2025: JSKN003 granted another breakthrough therapy designation in China for the treatment of patients with HER2-positive advanced colorectal cancer JSKN003, a biparatopic HER2-targeting antibody-drug conjugate co-developed by CSPC’s […]
Weekly Digest – October 2025 Weekly Digest – October 2025 21 October 2025: Padcev (Enfortumab vedotin) plus Keytruda (Pembrolizumab) sBLA granted FDA priority review for treatment of certain patients with muscle-invasive bladder cancer The FDA has accepted a supplemental Biologics License […]
Weekly Digest – October 2025 Weekly Digest – October 2025 23 October 2025: Heidelberg Pharma’s lead ADC Candidate HDP-101 granted fast track designation by US FDA for the treatment of multiple myeloma The US FDA granted fast track designation to […]
Weekly Digest – October 2025 Weekly Digest – October 2025 21 October 2025: Takeda enters global strategic partnership with Innovent Biologics to bolster oncology pipeline with next-generation investigational medicines for treatment of solid tumors Takeda entered a global strategic partnership […]
